Comparison of the efficacy of insulin degludec/insulin aspart and insulin degludec/liraglutide in patients with type 2 diabetes
- Conditions
- type 2 diabetes
- Registration Number
- JPRN-UMIN000039221
- Lead Sponsor
- Minami Osaka Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 24
Not provided
1.Patients with a history of severe ketosis, diabetic coma or previous coma within 6 weeks of this study. 2.Patients with a history of severe hypoglycemia (diabetic coma or pre-coma and convulsions needing third person assistance) within 6 weeks of this study. 3.Patients with severe renal dysfunction (eGFR less than 30mL/min/1.73m2 or serum creatinine 2.0mg/dL and more) or end-stage renal failure on dialysis. 4.Patients with proliferative retinopathy (however, patients who have undergone photocoagulation and have stable symptoms can be included). 5.Patients with a history of surgery for severe gastrointestinal disease. 6.Pregnant or possibly pregnant and lactating patients. 7.Patients with severe infections, before and after surgery, with severe trauma. 8.Patients receiving systemic corticosteroids. 9.Patients with severe liver dysfunction (high AST or ALT 100 U/L and more). 10.Patients with a history of allergy to the drug to be used in this study. 11.Patients with malignancy or a history of malignancy. 12.Patients judged by the investigator to be inappropriate as subjects.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method